[HK]中国医疗集团(08225):（1）建议一般授权进行发行和回购股票；（2）退休董事的连任事宜；(3) 关于修改公司章程草案并通过第三次修订及重新表述后的公司章程；（4）股东周年大会通告
原标题:中国医疗集团:（1）建议一般授权进行发行和回购股票；（2）退休董事的连任事宜；(3) 关于修改公司章程草案并通过第三次修订及重新表述后的公司章程；（4）股东周年大会通告 CHINAHEALTHGROUPINC. 中國醫療集團有限公司 (CarryingonbusinessinHongKongas“萬全醫療集團”) (以「萬全醫療集團」名稱在香港經營業務) (IncorporatedintheCaymanIslandswithlimitedliability) (於開曼群島註冊成立之有限公司) (StockCode:08225) (股票代號:08225) THISCIRCULARISIMPORTANTANDREQUIRESYOURIMMEDIATEATTENTION 此乃要件請即處理Ifyouare inanydoubtastoanyaspectofthis 閣下如對本通函任何方面或應採取的行動有circularorastotheactiontobetaken,you 任何疑問，應諮詢閣下的持牌證券交易商、銀shouldconsultyourlicensedsecuritiesdealer, 行經理、律師、專業會計師或其他專業顧問。 bankmanager,solicitor,professionalaccountant orother professionaladviser. Ifyou havesoldortransferredallyourshares in ChinaHealthGroupInc.youshouldatonce 閣下如已售出或轉讓名下所有中國醫療集團有 handthiscircular,togetherwiththeenclosed 限公司股份，應立即將本通函連同隨附代表委任 formofproxy,tothe purchaserortransfereeor 表格交予買主或承讓人，或經手買賣或轉讓的銀 tothe bank,licensedsecuritiesdealerorother 行、持牌證券交易商或其他代理商，以便轉交 agentthroughwhomthesale ortransferwas 買主或承讓人。 effectedfortransmissiontothepurchaseror transferee. HongKongExchangesandClearingLimitedand 香港交易及結算所有限公司及香港聯合交易所有 TheStockExchangeofHongKongLimitedtake 限公司對本通函的內容概不負責，對其準確性或 noresponsibilityforthecontentsofthiscircular, 完整性亦不發表任何聲明，並明確表示概不就因 makenorepresentationastoitsaccuracyor 本通函全部或任何部分內容而產生或因倚賴該等 completenessandexpresslydisclaimanyliability 內容而引致的任何損失承擔任何責任。 whatsoeverforanylosshowsoeverarisingfrom orinrelianceuponthewholeoranypartofthe contentsofthiscircular. This circular, for which the directors of the 本通函（本公司各董事願共同及個別對此負全 Company collectively and individually accept full 責）乃遵照香港聯合交易所有限公司創業板證券 responsibility, includes particulars given in 上市規則的規定而提供有關本公司的資料。各董 compliancewiththe RulesGoverningthe Listingof 事經作出一切合理查詢後確認，就彼等所深知及 Securities on the Growth Enterprise Market ofThe 確信：(i)本通函所載資料在各重大方面均屬準確 Stock Exchange of Hong Kong Limited for the 及完整，且無誤導成分；(ii)並無遺漏任何其他事 purpose of giving information with regard to the 實致使本通函所載任何內容產生誤導；及(iii)本 Company. The Directors, having made all 通函內表達的一切意見乃經審慎周詳考慮後方作 reasonable enquiries, confirm that, to the best of 出，並以公平合理的基準和假設為依據。 their knowledge and belief, (i) the information contained inthis circular is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement herein misleading; and (iii) all opinions expressed herein have been arrived at after due and careful consideration and are founded on bases and assumptions that are fairand reasonable. CHINAHEALTHGROUPINC. 中國醫療集團有限公司 (CarryingonbusinessinHongKongas“萬全醫療集團”) (以「萬全醫療集團」名稱在香港經營業務) (IncorporatedintheCaymanIslandswithlimitedliability) (於開曼群島註冊成立之有限公司) (StockCode:08225) (股份代號:08225) PROPOSEDGENERALMANDATESTOISSUEANDREPURCHASESHARES, 提議一般授權進行發行和回購股票 RE-ELECTIONOFRETIRINGDIRECTORS重新選舉退任董事、PROPOSED AMENDMENTTOTHEARTICLESOFASSOCIATIONANDADOPTIONOFTHE THIRDAMENDEDANDRESTATEDARTICLESOFASSOCIATION 建議修訂組織章程細則及採納第三份經修訂及重述的組織章程細則 AND 和 NOTICEOFANNUALGENERALMEETING 股東周年大會通告 本公司董事會函件載於本通函第3至7頁。本公司 Aletterfromtheboardofdirectorsofthe Companyissetoutonpages3to7ofthiscircular. 謹訂於二零二六年七月十七日星期五上午十時正假 A noticeconveningtheannualgeneralmeeting 座北京市朝陽區建外SOHO17號樓舉行股東周年大會 oftheshareholdersoftheCompanytobeheldat ,召開大會之通告載於本通函第14至19頁。亦隨函 Building 17,JianwaiSOHO,ChaoyangDistrict, 附奉股東周年大會適用之代表委任表格。 BeijingChinaat10:00a.m.onFriday, 17July 2026 issetoutonpages14to19 ofthiscircular. A formofproxyforuseattheAGMisalso enclosedwiththiscircular. Whetherornotyouintendtoattendandvoteat 無論閣下是否打算親身出席股東周年大會並於會 theAGMinperson,youarerequestedto 上投票，務請儘快根據隨附代表委任表格上印備 completeandreturntheaccompanyingformof proxyinaccordancewiththeinstructionsprinted 之指示將其填妥，並將表格送達本公司之股份過 thereontotheCompany'sRegistrar,Tricor 戶登記處卓佳證劵登記有限公司，地址為香港 InvestorServicesLimited,at17/F.,FarEast 夏愨道16號遠東金融中心17樓，惟無論如何須於 FinanceCentre,16HarcourtRoad,HongKongas 股東周年大會或其任何續會指定舉行時間48小 soonaspossiblebutinanyeventnotlaterthan 48hoursbeforethetimeappointedforholding 時前交回。填妥及交回代表委任表格後，閣下仍AGMoranyadjournmentthereof.Completion 可親身出席股東周年大會及於會上投票。 andreturnoftheformofproxywillnotpreclude youfromattendingandvotingattheAGMin personifyousowish. This circular will remain on the“LatestListed 本通函將由刊登日期起計最少七天刊載於創業板Company Information” page of the Stock 網站www.hkexnews.hk「最新公司公告」一頁及 Exchange'swebsite atwww.hkexnews.hk and www.chgi.net 本公司網站 內。 on theCompany'swebsiteatwww.chgi.netfor atleast7daysfromthedateofitspublication. 25June 2026 二零二六年六月二十五日 *Foridentificationpurposeonly CHARACTERISTICSOFGEM 香港聯合交易所有限公司創業板的特色GEM has been positioned as a market 創業板之定位，乃為相比起其他在聯交所上市 designed to accommodate companies to 之公司帶有較高投資風險之公司提供一個上市 which a higher investment risk may be 之市場。有意投資者應瞭解投資於該等公司之 attachedthanothercompanieslistedonthe 潛在風險，並應經過審慎周詳之考慮後方作出 Stock Exchange. Prospective investors 投資決定。創業板之較高風險及其他特色表示 should be aware of the potential risks of 創業板較適合專業及其他經驗豐富投資者。 investing in such companies and should makethedecisiontoinvestonlyafterdue and careful consideration. The greater risk profile and other characteristics of GEM meanthatitisamarket moresuited to professional and other sophisticated investors. Given the emerging nature of companies listed on GEM, there is a risk that securities 由於創業板上市公司之新興性質所然，在創 traded on GEM may be more susceptible to 業板買賣證券可能會較於聯交所主機板買賣 high market volatility than securities traded 證券承受較大之市場波動風險，同時無法保 onthe Main BoardoftheStock Exchangeand 證在創業板買賣證券會有高流通量市場。 no assurance is given that there will be a liquidmarketinthesecuritiestradedonGEM. DEFINITIONS 釋義Inthiscircular,unlessthecontextotherwiserequires,thefollowingexpressionshavethefollowingmeanings:於本通函內，除文義另有所指外，下列詞具具有以下涵義： theannualgeneralmeetingoftheCompanytobeconvenedandheldatBuilding17,Jianwai“AGM” SOHO,ChaoyangDistrict,BeijingChinaat10:00a.m.onFriday,17July2026本公司謹訂於二零二六年七月十七日星期五上午十時正假座北京市朝陽區建外SOHO17號樓召開及舉行之股東周年大會 「股東周年大會」 thenoticeoftheAGMsetoutonpages14to19ofthis circular “AGMNotice” 本通函第14至19頁所載股東周年大會通告 「股東周年大會通告」 “ArticlesofAssociation” thearticlesofassociationoftheCompany(asamendedfromtimetotime)「組織章程細則」 本公司組織章程（經不時修訂） “associate(s)” hasthemeaningascribedtheretointheGEMListingRules具創業板上市規則所賦予之涵義 「聯繫人士」 “Board” theboardofDirectors 「董事會」 董事會 adayonwhichtheStockExchangeisopenforthebusinessofdealinginsecurities“BusinessDay” 聯交所開業買賣證券之日子 「營業日」 theCompaniesAct,Cap.22(Act3of1961,asconsolidatedandrevised)ofCaymanIslands,“Companies asamended,modifiedandsupplementedfromtimetotime Act”「公司法」 經不時修訂、修改及補充之開曼群島法例第22章公司法（一九六一年第3號法例，經綜合及修訂）“Company” ChinaHealthGroupInc.,acompanyincorporatedintheCaymanIslandswithlimitedliability「本公司」 andtheSharesofwhicharelistedonGEMwithstockcode:8225 中國醫療集團有限公司，一家於開曼群島成立之有限公司，其股份於聯交所創業板上市，股份代號：8225 hasthemeaningascribedtheretointheGEMListingRules “connectedperson(s)” 具創業板上市規則所賦予之涵義 「關連人士」 hasthemeaningascribedtheretointheGEMListingRules 具創業板上市規則所賦予之涵義 “controllingshareholder(s)” 「控股股東」 thedirector(s)oftheCompany “Director(s)” 本公司董事 「董事」 anyperson(s)whosatisfiestheeligibilitycriteriaundertheNewShareOptionScheme任何符合新購股權計畫項下合資格標準之人士 “EligibleParticipant(s)” 「合資格參與者」 a general and unconditional mandate proposed to begranted bythe Company tothe Directorstothe effect that the aggregate nominalvalue ofthe Shares which may be allotted and issued under“ExtensionMandate” the Issue Mandate may be extended by an addition of an amount representing the aggregate「擴大授權」 nominalvalueofShares repurchased underthe Repurchase Mandate本公司擬向董事授出之一般及無條件授權，以可能擴大根據發行授權可能配發及發行股份之總面值，擴大金額相當於根據購回授權所購回股份之總面值 theGrowthEnterpriseMarketoftheStockExchange “GEM” 聯交所創業板 「創業板」 TheRulesGoverningtheListingofSecuritiesonGEM “GEMListing Rules” 創業板證券上市規則 「創業板上市規則」 any Eligible Participant(s)who accepts an Offer in accordancewiththe terms ofthe New“Grantee(s)” Share Option Scheme or, where the context so permits, a legal personal representative「承授人」 entitledtoanysuchOptionsinconsequenceofthedeathoftheoriginalGrantee(s)TheCompanyanditssubsidiariesfromtimetotime “Group” 「本集團」 本公司及其不時之附屬公司 HongKongdollars,thelawfulcurrencyofHongKong “HK$” 港元，香港之法定貨幣 「港元」 TheHongKongSpecialAdministrativeRegionofthePRC “HongKong” 中國香港特別行政區 「香港」 “IssueMandate” A general and unconditional mandate proposed to be granted by the company to the 「發行授權」 directorstoallot,issueanddealwithshareswithanaggregatenominalvaluenotexceeding 20%oftheaggregatenominalvalueofthesharecapitalofthecompanyinissueasatthe dateofpassingtherelevantresolutionattheAGM 本公司擬授予董事之一般及無條件授權，以配發、發行及處理總面值不超過本公司於股東周年大會通 過相關決議案日期已發行股本總面值20%之股份 “PRC” ThePeople’sRepublicofChina 中華人民共和國 A general and unconditional mandate proposed to be granted by the company to the “Repurchase directorsto repurchasethesharesonthestockexchangewithanaggregate nominalvalue Mandate” 「購回授權」 notexceeding 10%oftheaggregatenominalvalueofthesharecapitalofthecompanyin issueasatthedateofpassingtherelevantresolutionattheAGM 本公司擬授予董事之一般及無條件授權，以於聯交所購回總面值不超過本公司於股東周年大會通過 相關決議案當日已發行股本總面值10%之股份 “Last Practicable Date” 23June2026,beingthelatestpracticabledatepriortotheprintingofthiscircularforthe 「最後可行日期」 purposeofascertainingcertaininformationcontainedherein 二零二六年六月二十三日，即刊印本通函前就確認當中所載若干資料之最後實際可行日 期 “SFO” Thesecuritiesandfuturesordinance(chapter571ofthelawsofhongkong) 「證券及期貨條例」 香港法例第571章證券及期貨條例 “Share(s)” Theordinaryshare(s)ofHK$0.10eachinthesharecapitaloftheCompany本公司股本中每股面值0.10港元之普通股 “Shareholder(s)” Holder(s)oftheshare(s) 「股東」 股份持有人 “StockExchange” TheStockExchangeofHongKongLimited 「聯交所」 香港聯合交易所有限公司 “Subscription ThepricepershareatwhichagranteemaysubscribeforsharesontheexerciseofanoptionPrice”「認購價」 承授人於行使購股權時可能認購股份之每股股份價格“Subsidiary(ies)” Acompany(ies)whichis/areforthetimebeingandfromtimetotimeasubsidiary(ies)within「附屬公司」 the meaningoftheCompaniesOrdinance(Chapter622ofthe Lawsof Hong Kong)oftheCompany,whetherincorporatedinHongKongorelsewhere 當時及不時屬本公司附屬公司（定義見香港法例第622章公司條例）之公司，無論是否於香港或其他地方註冊成立 “substantialshareholder(s)” 「主要股東」 HasthemeaningascribedtheretointheGEMListingRules具創業板上市規則所賦予之涵義 "ThirdAmendedandRestated ArticlesofAssociation" "ThethirdamendedandrestatedarticlesofAssociationproposedtobeadopted「第三次经修订及重述的公司章程 attheannualGeneralMeetingassetoutinAppendixIIItothiscircular"细则」 拟于股东周年大会上采纳并载于本通函附录III的第三次经修订及重述的公司章程细则“TakeoversCode” 「收購準則」 HongKongCodeonTakeoversandMergers 香港公司收購及合併守則 “%” 「%」 Percent. LETTERFROMTHEBOARD 董事會函件CHINAHEALTHGROUPINC. 中國醫療集團有限公司 (CarryingonbusinessinHongKongas“萬全醫療集團”) (以「萬全醫療集團」名稱在香港經營業務) (IncorporatedintheCaymanIslandswithlimitedliability) (於開曼群島註冊成立之有限公司) (StockCode:8225) (股份代號:8225) 執行董事： Executive Directors: 郭夏先生（主席） Mr.GUO Xia(Chairman) 郭瑞萌先生 Mr. RaymondGUO 非執行董事： Non-executive Director: 張麗博士 Dr. ZHANGLi 獨立非執行董事： Independentnon-execiutveDirtectors: 伍霜馴先生 Mr.WUShuangsi 倪彬暉博士 Dr. NIBinhui 郭彤博士 Dr. GUOTong 劉娜女士 Ms.LIUNa 註冊辦事處： Registeredoffice: Vistra(Cayman)Limited Vistra(Cayman)Limited 開曼群島 P.O. Box31119GrandPavilion 大開曼島 HibiscusWay, 西灣道802號 802WestBayRoad, 芙蓉路宏閣 GrandCayman, 郵箱31119 KY1-1205 KY1-1205 Cayman Islands 總辦事處： Headoffice: 中國北京 Building17,JianwaiSOHO, 朝陽區 ChaoyangDistrict, 建外SOHO17號樓 Beijing,China 香港主要營業地點及總辦事處: Principal placeofbusinessand 香港 headoffice inHongKong: 灣仔灣仔道 133號卓淩中心 UnitB,19/F. 19樓B室 Times MediaCentre 133WanchaiRoad,WanchaiHongKong LETTERFROMTHEBOARD 董事會函件DearSirorMadam 敬啟者： PROPOSEDGENERALMANDATESTOISSUEANDREPURCHASESHARES, 建議發行及購回股份之一般授權, PROPOSEDRE-ELECTIONOFRETIRINGDIRECTORS重選退任董事、PROPOSEDAMENDMENTTOTHEARTICLESOFASSOCIATIONANDADOPTIONOFTHETHIRDAMENDEDANDRESTATEDARTICLESOFASSOCIATION, 建議修訂組織章程細則及採納第三份經修訂及重述的組織章程細則, AND 及 NOTICEOFANNUALGENERAL MEETING 股東周年大會通告 1.INTRODUCTION 1.緒言 The purpose of this circular is to provide you with information in respect of the (i) the proposed 本通函旨在向閣下提供有關：(i)建議授予董事發行及(ii)購 回股份之一般授權及創業板上市規則規定之其他資料，以 general mandates for the issue and repurchase of 便閣下就投票贊成或反對將於股東周年大會上提呈之決議 sharesto begrantedtothe Directorsand (ii) other 案作出知情決定。 information required underthe GEM Listing Rules to enable you to make an informed decision on whether to vote for or against the resolutions tobe proposedattheAGM. 2.PROPOSED GENERAL MANDATES TO ISSUE 2.建議授予發行授權、回購授權和擴額授權 ANDREPURCHASESHARES AtthelastannualgeneralmeetingoftheCompany,general 於本公司在上屆股東周年大會上，本公司授予董事一般授權 mandatesweregivenbytheCompanytotheDirectors(a)to allot,issueanddealwithSharesnotexceeding20%ofthe 以(a)配發、發行及處理不超過於決議案通過當日本公司已發 aggregatenominalamountofthesharecapitalofthe 行股本面值總額 20%之股份；(b)在聯交所購回面值總額不 Companyinissueasatthedateofthepassingofthe 超過於決議案通過當日本公司已發行股本面值總額 10%之 resolution;(b)torepurchasetheSharesontheStock 股份；及(c)透過增加相當於購回授權項下購回股份之面值總 Exchangewithanaggregatenominalvaluenotexceeding10% 額之金額，將可能根據發行授權配發及發行之股份之面值總 oftheaggregatenominalvalueofthesharecapitalofthe Companyinissueasatthedateofpassingoftheresolution;and 額擴大。該等一般授權將在股東周年大會結束時失效。 (c)totheeffectthattheaggregatenominalvalueoftheShares whichmaybeallottedandissuedundertheissue mandatemaybeextendedbyanadditionofanamount representingtheaggregate nominalvalueofShares repurchasedundertherepurchasemandate.Suchgeneral mandateswill lapseattheconclusionoftheAGM. AttheAGM,thefollowingresolutions,amongothermatters, 下列決議案（其中包括）將在股東周年大會上提呈： willbeproposed: (a)togranttheIssueMandatetotheDirectorstoexercisethe powersoftheCompanytoallot,issueanddealwiththe (a)授予董事發行授權以行使本公司之權力，配發、發行及 Shares uptoamaximumof20%oftheaggregatenominal 處理最多為通過有關決議案當日本公司已發行股本面值總 amountofthesharecapitaloftheCompanyinissueasatthe 額 20%之股份； dateof passingofsuchresolution; (b)togranttheRepurchaseMandatetotheDirectorsto enablethemtorepurchasetheSharesuptoamaximumof10% oftheaggregatenominalamountofthesharecapitalof (b)授予董事購回授權，以令彼等購回最多為通過該決議 theCompanyinissueasatthedateofpassingofsuch 案當日本公司已發行股本面值總額10%之股份； resolution;and (c)togranttheExtensionMandatetotheDirectorsto increasethetotalnumberofShareswhichmaybeallotted (c)授予董事擴大授權，以透過增加相當於購回授權項下購 andissuedundertheIssueMandatebyanadditional 回股份數目之數額增加可能根據發行授權配 發及發行之股 numberrepresentingsuchnumberofSharesrepurchased 份總數。 undertheRepurchaseMandate. AsattheLatestPracticableDate,theissuedsharecapital of theCompanycomprised995,351,660Shares.Subjecttothe 於最後可行日期，本公司已發行股本包括995,351,660股 passingoftheresolutionsapprovingtheIssue 股份。待批准發行授權及購回授權之決議案於股東周年 MandateandtheRepurchaseMandateattheAGMand LETTERFROMTHEBOARD 董事會函件AsattheLatestPracticableDate,theissuedsharecapitalof 並假設本公司已發行股本於最後可行日期至股東周年大會日 theCompanycomprised995,351,660Shares.Subjecttothe 期期間概無變動，根據發行授權可能發行之最高股份數目 passingoftheresolutionsapprovingtheIssueMandateand theRepurchaseMandateattheAGMandassumingthat 將為199,070,332 股（相當於有關決議案通過當日已發行股 thereisnochangeintheissuedsharecapitalofthe 份總數 20%）及根據購回授權可能購回之最高股份數目將 CompanybetweentheLatestPracticableDateandthedate 為 99,535,166股（相當於有關決議案通過當日已發行股份 oftheAGM,themaximumnumberofShareswhichmaybe issuedpursuanttotheIssueMandatewillbe199,070,332 總數 10%）。 Shares(representing20%ofthetotalnumberofSharesin issueasatthedateofpassingoftherelevantresolution)and themaximumnumberofShareswhichmayberepurchased pursuanttotheRepurchaseMandatewillbe99,535,166 Shares(representing10%ofthetotalnumberofSharesin issueasatthedateofpassingoftherelevantresolution). EachoftheIssueMandate,theRepurchaseMandateandthe 發行授權、購回授權及擴大授權將於下列日期（以最早 ExtensionMandatewillexpireattheearliestof:(a)the 者為准）屆滿：(a)本公司下屆股東周年大會結束之時； conclusionofthenextannualgeneralmeetingofthe (b)任何開曼群島適用法例或組織章程細則規定本公司須 CompanyfollowingtheAGM;(b)thedatebywhichthenext 舉行下屆股東周年大會之日；或(c)股東於下屆股東周年 annualgeneralmeetingisrequiredbyanyapplicablelawof 大會之前在本公司股東大會上透過普通決議案撤銷或更 theCaymanIslandsortheArticlesofAssociationtobeheld; or(c)whenthemandatesarerevokedorvariedbyordinary 改該等授權之時。 resolution(s)oftheShareholdersinageneralmeetingofthe Companypriortothenextannualgeneralmeetingofthe CompanyfollowingtheAGM. UndertheGEMListingRules,theCompanyisrequiredto 根據創業板上市規則，本公司須向股東提供一切合理所需givetotheShareholdersallinformationwhichisreasonably 資料，以便股東就在股東周年大會上投票贊成或反對有關 necessarytoenabletheShareholderstomakeaninformed 購回授權之決議案作出知情決定。購回授權說明函件載於 decisionastowhethertovotefororagainsttheresolutionin 本通函附錄一。 respectoftheRepurchaseMandateattheAGM.An explanatorystatementontheRepurchaseMandateissetout inAppendixItothiscircular. 3.PROPOSEDRE-ELECTIONOFDIRECTORS 3.提議連任董事 AsattheLatestPracticableDate,theBoardconsistedofseven 截至最後可行日期，董事會由七名董事組成。即 Directors,namely: EXECUTIVEDIRECTORS 執行董事 郭夏先生（主席） Mr.GUOXia(Chairman) 郭瑞萌先生 Mr.RaymondGUO NON-EXECUTIVEDIRECTOR 非執行董事 Dr.ZHANGLi 張麗博士 INDEPENDENTNON-EXECUTIVEDIRECTORS Mr.WUShuangsi 獨立非執行董事 Dr.NIBinhui 伍霜駟先生 Dr.GUOTong 倪彬暉博士 Ms.LIUNa 郭彤博士 劉娜女士 InaccordancewiththeArticlesofAssociation,Dr.GUO 根據公司章程，郭彤博士、郭夏先生和刘娜女士將於股東 Tong,Mr.GUOXia,Ms.LIUNawillretireattheAnnual 周年大會上退任，所有這些董事均符合資格，並表示願意 GeneralMeetingandalltheseDirectors,beingeligible, 重選連任。 haveofferedthemselvesforre-election. BiographicaldetailsofeachoftheretiringDirectorsare 各退任董事的履歷詳見本通函附錄二。 setoutinAppendixIItothiscircular. LETTERFROMTHEBOARD 董事會函件4.PROPOSEDAMENDMENTTOTHEARTICLESOF 4.建議修訂組織章程細則及採納第三份經修訂及重述的組織章程細則 ASSOCIATIONANDADOPTIONOFTHETHIRD AMENDEDANDRESTATEDARTICLESOFASSOCIATION 董事會建議透過採納第三次經修訂及重述的公司章程細則（ TheBoardproposestoamendtheexistingArticlesofAssociationby 「新章程細則」）以修訂現有章程細則，從而使現有章程細 adoptingtheThirdAmendedandRestatedArticlesofAssociationin 則符合最新的法律及監管規定，包括於2025年7月1日生效的 ordertobringtheexistingArticlesofAssociationinlinewiththelatest《上市規則》附錄A1有關核心股東保障標準的修訂。 legalandregulatoryrequirements,includingtheamendmentsmadeto 建議修訂章程細則（「建議修訂」）的主要詳情包括： AppendixA1totheListingRulesonCoreShareholderProtection Standards,whichbecameeffectiveon1July2025. ThemaindetailsoftheproposedamendmentstotheArticlesof 更新法例引用：以對應現行《開曼群島公司法》（經修訂） Association(the“ProposedAmendments”)include: 的條文，取代對開曼群島《公司法》及《電子交易法》的過 Updateoflegislativereferences:Replaceoutdatedreferencestothe時引用； CaymanIslandsCompaniesActandtheElectronicTransactionsLaw withprovisionscorrespondingtothecurrentCaymanIslands 股東大會規則：完善有關股東大會通告、暫停辦理股份過戶 CompaniesAct(asamended);Generalmeetingrules:Refineprovisions登記及投票程序的條文，以全面符合《GEM上市規則》附錄 relatingtonoticeofgeneralmeetings,closureofregisterofmembers,andvotingprocedures,tofullyalignwiththemandatoryrequirements三所載的強制性規定； setoutinAppendixIIItotheGEMListingRules;Electronicdeliveryandmeetings:Improvedefinitionsandoperationalrulesforelectronic 電子送達及會議：改進有關文件電子送達、網上會議及書面 deliveryofdocuments,onlinemeetingsandwrittennotices,tocomply通知的定義及運作規則，以符合最新的監管規定； withthelatestregulatoryrequirementsondocumenttransmission; Shareschemeprovisions:Supplementsupportingprovisionsrelatingto股份計劃條文：補充有關股份計劃及購股權的配套條文，以 shareschemesandshareoptionstomatchtherequirementsof Chapter23oftheGEMListingRulesonshareincentiveschemes; 配合《GEM上市規則》第23章有關股份激勵計劃的規定； Governanceprovisions:Fine-tunethegovernanceprovisionsforthe Board,theRemunerationCommitteeandtheAuditCommitteeto 管治條文：優化董事會、薪酬委員會及審核委員會的管治條 reflectupdatesintheCorporateGovernanceCode;Textualand 文，以反映《企業管治守則》的最新修訂； definitionalrefinements:Streamlinedefinitions,removeobsoleteprovisions,andimprovetheoveralllogicoftheArticles,without 文字及定義優化：理順定義、刪除已失效的條文，並改善章 prejudicetoanystatutoryrightsofshareholders. 程細則的整體邏輯，惟不損害股東的任何法定權利。 FordetailsoftheProposedAmendments,pleaserefertoAppendixIII tothiscircular.TheProposedAmendmentsandtheproposedadoption 有關建議修訂的詳情，請參閱本通函附錄三。建議修訂及採 oftheThirdAmendedandRestatedArticlesofAssociation 納納入該等建議修訂的第三次經修訂及重述的公司章程細則 incorporatingtheProposedAmendmentsaresubjecttotheapproval ，須經股東於股東周年大會上以特別決議案方式批准，並將 oftheShareholdersbywayofaspecialresolutionattheAGM,andwill 於該特別決議案獲通過後生效。 takeeffectsubjecttothepassingofsuchspecialresolution. Pursuanttoarticle177oftheexistingArticlesofAssociation,the proposedamendmentsandtheadoptionoftheThirdAmendedand 根據現有章程細則第177條，建議修訂及採納第三次經修訂 RestatedArticlesofAssociationaresubjecttotheShareholders’ 及重述的公司章程細則須經股東於股東周年大會上以特別決 approvalbywayofspecialresolutionattheAnnualGeneralMeeting. 議案方式批准。 ThelegaladviserstotheCompanyastoHongKonglawsandCayman IslandslawshaverespectivelyconfirmedthattheProposed 本公司有關香港法律及開曼群島法律的法律顧問已分別確認 AmendmentscomplywiththerequirementsoftheGEMListingRules, whereapplicable,andarenotinconsistentwiththelawsoftheCayman ，建議修訂在適用範圍內符合《GEM上市規則》的規定，且 Islands.TheCompanyalsoconfirmsthatthereisnothingunusual 與開曼群島法律並無抵觸。本公司亦確認，建議修訂對一家 abouttheProposedAmendmentsforacompanylistedinHongKong. 香港上市公司而言並無異常之處。 TheCompanyconfirmsthatthereisnothingunusualabouttheThird Amended and Restated Articles of Association. The Shareholders are本公司確認，第三次經修訂及重述的公司章程細則並無異常 advisedthattheThirdAmendedandRestatedArticlesofAssociation areavailableonlyin English andtheChinesetranslation oftheThird 之處。謹此提醒股東，第三次經修訂及重述的公司章程細則 AmendedandRestatedArticlesofAssociationprovidedinAppendixIII僅備有英文版本，本通函附錄三所載的中文譯本僅供參考。 of this circular in Chinese is for reference only. In case of any如有任何歧異，概以英文版本為準。 inconsistency,theEnglishversionshallprevail. LETTERFROMTHEBOARD 董事會函件5.續聘核數師 5.RE-APPOINTMENTOFTHEAUDITORS 中瑞和信會計師事務所有限公司將於股東周年大會上退 KTCPartnersCPALimitedwillretireastheauditorsofthe CompanyattheAGMand,beingeligible,offerthemselves 任本公司核數師，惟符合資格並願意重選連任。董事會經審 forre-appointment.TheBoard,upontherecommendation 核委員會推薦，建議續聘中瑞和信會計師事務所有限公司為 of the audit committee of the Board, proposed to re- appoint KTC Partners CPA Limited as the auditors of the 本公司核數師，任期直至本公司下屆股東周年大會結束為止 Company and to hold office until the conclusion of the 。 next annual general meeting of the Company. The estimatedaudit fee payable to KTCPartners CPA Limited 本公司就審核本公司及其附屬公司截至二零二六年十二 for the audit of the consolidated financial statements of the Company and its subsidiaries for the financial year 月三十一日止財政年度之綜合財務報表應付中瑞和信會計師 ending31December2026isexpectedtobeintherange 事務所有限公司之估計審計費用，預期約為人民幣50萬元至 ofapproximatelyRMB500,000toRMB550,000(exclusive ofout-of-pocketexpenses). 人民幣55萬元（不包括實報實銷開支）。 The estimated audit fee has been determined after due consideration and arm’s length negotiations between the 該估計審計費用乃經本公司與中瑞和信會計師事務所有 Company and KTC Partners CPA Limited taking into 限公司公平磋商，並已適當考慮（其中包括）反映本集團業 account, among other matters, allocation of time and resources required reflecting the size, complexity and 務規模、複雜程度及地域分佈所需之時間及資源分配、審計 geographical spread of the Group’s operations, the audit 時間表，以及就處理所識別重大風險所需審計工作之風險評 timetableandriskassessmentintermsoftheauditeffort 估等因素後厘定。該估計審計費用亦假設於本財政年度內， required to address identified significant risks. The estimated audit fee also assumes that there will be no 本集團之架構、業務模式或營運不會出現先前未向中瑞和信 materialchangetotheGroup’sstructure,businessmodels 會計師事務所有限公司傳達之重大變動，且本公司將就審計 oroperationsduringthefinancialyearthathavenotbeen previously communicated to KTC Partners CPA Limited, 工作適時提供足夠及所需之協助及資料。 and that the Company will provide timely and adequate assistanceandinformationasreasonablyrequiredforthe 除非上述基準或假設出現重大變動，否則最終審計費用 purposesoftheaudit. 不應與最初披露之估計金額出現重大偏差。倘出現任何重大 Unless there is a material change in the basis or assumptionssetoutabove,thefinalauditfeeshouldnot 變動，本公司將適時另行刊發披露。 deviate materially from the estimated amount initially disclosed. In the event of any material change, the Companywillmakefurtherdisclosureasappropriate. LETTERFROMTHEBOARD 董事會函件6.THEAGM 6.股東周年大會 本公司謹訂於二零二六年七月十七日星期五上午十 A notice of convening the AGM to be held at Building 17,JianwaiSOHO,Chaoyang District, Beijing 時正假座北京市朝陽區建外SOHO17號樓召開股東 Chinaat10:00a.m.onFriday 17 July 2026issetout 周年大會，大會通告載於本通函第 14至19頁。 onpages14to19ofthiscircular. 本通函亦附奉股東周年大會適用之代表委任表格。 Aformofproxyforuse at the AGM is also enclosedwiththiscircular. 無論閣下能否親身出席股東周年大會並於會上投 ofproxyinaccordancewiththeinstructionsprinted 票，務請儘快根據隨附代表委任表格上印備之指示 thereontotheCompany'sRegistrar,TricorInvestor 將其填妥，並將表格送達本公司之股份過戶登記處 Services Limited,at17/F.,FarEastFinanceCentre,16 卓佳證劵登記有限公司，地址為香港夏愨道16號遠東 HarcourtRoad,HongKong,assoonaspossiblebut 金融中心17樓，惟無論如何須於股東周年大會或其任 inanyeventnotlaterthan48hoursbeforethetime 何續會指定舉行時間48小時前交回，方為有效。 appointedforholdingAGMoranyadjournment 填妥及交回代表委任表格後，閣下仍可親身出席股 thereof.Completionandreturnoftheformofproxy 東周年大會並於會上投票。 willnotprecludeyoufromattendingandvotingat theAGMinpersonifyousowish. 7.投票表決 7.VOTINGBYPOLL 根據創業板上市規則第 17.47(4)條，股東於股東大會 Accordingto Rule 17.47(4)oftheGEM Listing Rules, 上所作任何表決均須以投票表決方式進行（惟主席 anyvote ofshareholders at a general meeting must be taken by poll (exceptwherethe chairman of the 以誠實信用原則作出決定，容許純粹關於程式或行 meeting, ingoodfaith,decidestoallowa resolution 政事宜之決議案以舉手方式表決除外）。因此， 股 whichrelatespurelytoaproceduraloradministrative 東周年大會主席要求所有於股東周年大會提呈之決 matter to be voted on by a show of hands). The 議案將以投票表決方式進行表決。 chairmanoftheAGMwillthereforedemandapollfor alltheresolutionsputtothevoteattheAGM. 據董事作出一切合理查詢後所深知、全悉及確信 TothebestoftheDirectors’knowledge,information 概無股東須就將於股東周年大會上提呈之決議 andbelief, havingmadeallreasonableenquiries, ， 案放棄投票。 noShareholderisrequiredtoabstainfromvoting ontheresolutionstobeproposedattheAGM. 本公司將於股東周年大會結束後就股東周年大會 TheCompanywillpublishanannouncementonthe 投票表決結果刊登公佈。 pollresultsoftheAGMaftertheconclusionofthe AGM. 8.推薦意見 8.RECOMMENDATION TheBoardisoftheviewthattheIssueMandate 董事會認為，發行授權、購回授權及擴大授權，建theRepurchaseMandateandtheExtension 議重選董事以及建議採納新購股權計畫符合本公司Mandate,theproposedre-electionofDirectors 及其股東之整體最佳利益。因此，董事會建議股東 andtheproposedadoptionoftheNewShare 投票贊成股東周年大會通告所載之所有決議案。 OptionSchemeareinthebestinterestsofthe CompanyanditsShareholdersasawhole. Accordingly,theBoardrecommendsthatthe Shareholdersvoteinfavourofallresolutionsasset outintheAGMNotice. LETTERFROMTHEBOARD 董事會函件9.CLOSUREOFREGISTEROFMEMBERS 9.暫停辦理股份過戶登記 Thetransferbooksandregisterofmembersofthe 本公司將由二零二六年七月十四日星期二至二零二六年七月 CompanywillbeclosedfromTuesday,14July2026 十七日星期五（包括首尾兩日）期間暫停辦理股份過戶登 to Friday,17July2026,bothdaysinclusive,for 記，以確定股東出席股東周年大會及於會上投票之權利。為 thepurposeofdeterminingShareholders' 合資格出席股東周年大會並於會上投票，所有過戶檔連同有 entitlementstoattendandvoteattheAGM. Inorder 關股票須於二零二六年七月十三日星期一下午四時三十分前交回本公司之香港股份過戶登記處卓佳證劵登記有限公司， toqualifyfortherighttoattendandvoteatthe 地址為香港夏愨道16號遠東金融中心17樓。 meeting,alltransfers,accompaniedbytherelevant sharecertificates,mustbelodgedwiththeCompany's HongKongshareregistraratTricorInvestorServices Limited,at17/F,FarEastFinanceCentre,16Harcourt Road,HongKongnotlaterthan4:30p.monMonday ,13 July2026. 10.責任聲明 10.RESPONSIBILITYSTATEMENT 本通函乃遵照創業板上市規則之規定而提供有關本公 ThiscircularforwhichtheDirectorscollectivelyand 司之資料，各董事願就此共同及個別承擔全部責任。 individuallyacceptfullresponsibility,includes 各董事經作出一切合理查詢後確認，就彼等所深知及 particularsgivenincompliancewiththeGEMListing 確信，本通函所載資料在各重大方面均屬準確及完整 Rulesforthepurposeofgivinginformationwith ,且無誤導或欺詐成分，亦無遺漏任何其他事實致使 regardtotheCompany.TheDirectors,havingmade 本通函所載任何聲明或本通函有所誤導。 all reasonableenquiries,confirmthattothebest oftheirknowledgeandbelieftheinformation containedinthiscircularisaccurateandcomplete inallmaterialrespectsandnotmisleadingor deceptive,andtherearenoothermattesthe omissionofwhichwouldmakeanystatementhere inorthiscircularmisleading. 11.COMPETINGINTERESTS 11.競爭性權益 To the best knowledge of the Directors, as at the 就董事所深知，於最後可行日期，概無董事或彼 Latest Practicable Date, none of the Directors or 等各自之聯繫人士在與本集團業務直接或間接構 their respective associates had any interests in a 成競爭或可能構成競爭之業務中擁有鬚根據創業 business, which competes or is likely to compete 板上市規則第11.04條規定披露之任何權益，猶 eitherdirectlyorindirectlywiththebusinessofthe 如董事為控股股東。 Group which would be required to be disclosed underrule11.04 oftheGEMListing Rules, asifthe Directorswerecontrollingshareholders. 本通函及隨附代表委任表格之中英文版本如有差 The English texts of this circular and the 異，概以英文版本為准。 accompanying proxy form shall prevail overthe Chinesetextsincaseofinconsistency. ByorderoftheBoard 代表董事會 ChinaHealthGroupInc. 中國醫療集團有限公司 GUOXia 郭夏 Chairman 主席 HongKong,25June 2026 香港，二零二六年六月二十五日 APPENDIX1EXPLANATORYSTATEMENTONTHEREPURCHASEMANDATE 附錄一購回之說明文件This appendix serves as an explanatory statement, 根據創業板上市規則規定，作為說明函件，本附錄 as required by the GEM Listing Rules, to provide 提供所需資料以使股東可就投票贊成或反對有關批 requisite information to enable Shareholders to 准授出購回授權之決議案作出知情決定。 make an informed decision as to whether to vote for or against the resolution to approve the grant ofthe RepurchaseMandate. 1. 有關購回股份之創業板上市規則 1. GEMLISTINGRULESRELATINGTOTHE REPURCHASEOFSHARES The GEM Listing Rules permit companies whose 創業板上市規則允許以創業板為第一上市地之公司 primary listing is on GEMto repurchasetheir shares 於創業板或公司證券上市並獲香港證券及期貨事務 on GEM or any other stock exchange on which the 監察委員會及創業板認可的任何其他證券交易所購 securities of the Company are listed and such 回本身之股份，惟受若干限制所限。在該等限制 中， exchangeisrecognizedbytheSecuritiesand Futures 創業板上市規則規定，該等公司之股份須為已繳足 Commission of Hong Kong and GEM subject to 股份，該等公司購回股份均須事先經股東以普通決 certainrestrictions.Amongsuchrestrictions,theGEM 議案（無論以一般購回授權或以某一特定交易 的特 Listing Rules provide that the shares of such 定批准）批准。 companies must befully paid up and all repurchase of shares by such companies must be approved in advance by an ordinary resolution of shareholders, eitherbywayofageneralrepurchasemandateorby specificapprovalofaparticulartransaction. 2.股本 2. SHARECAPITAL 按最後可行日期已發行股份995,351,660股計 Exercise in full of the Repurchase Mandate (on the basis of 995,351,660 Shares in issue as atthe Latest 算並假設於最後可行日期至股東周年大會日期並 Practicable Date) would result in up to 99,535,166 無發行或購回股份，全面行使購回授權將使本 Shares (representing 10% ofthe issued sharecapital 公司於有關期間（定義見有關決議案）購回最多 of the Company as at the date of passing of the 99,535,166股股份（相當於本公司於有關決議 relevant resolution) being repurchased by the 案獲通過當日已發行股本之10%）。 Company during the Relevant Period (as defined in the relevant resolution), assuming no Shares are issuedorrepurchasedbetweentheLatest Practicable DateandthedateofAGM. 3.購回理由 3. REASONSFORREPURCHASE 董事相信，向股東徵求一般授權使董事可購回股份， The Directors believethat it is inthe best interests 符合本公司及股東之最佳利益。視乎當時市況及資 of the Company and the Shareholders to have a 金安排而定，有關購回可能會提升每股股份之 資產 general authority from the Shareholdersto enable the Directors to repurchase Shares. Such 淨值及/或盈利，並僅會於董事認為有關購回將對repurchases may,depending on market conditions 本公司及股東有利之情況下方會進行。 and funding arrangements at the time, lead to an enhancement in the net asset value and/or earnings per Share and will only be made when the Directors believe that such repurchases will benefittheCompanyandtheShareholders. APPENDIX1EXPLANATORYSTATEMENTONTHEREPURCHASEMANDATE 附錄一購回之說明文件4. 購回資金 4. FUNDINGOFREPURCHASES 根據本公司組織章程細則、公司法及開曼群島其他適 RepurchasesmadepursuanttotheRepurchaseMandate 用法例，根據購回授權購回股份將由合法可作此用途 wouldbefundedoutoffundslegallyavailableforthe 之資金撥付。根據公司法規定，本公司進行購回所用 purposeinaccordancewiththeArticlesofAssociationofthe 資金只可來源於本公司利潤或就此新發行股份之所得 CompanytheCompaniesLawandotherapplicablelawsof 款項，或組織章程細則批准及公司法所規定之資金。 theCaymanIslands.UndertheCompaniesAct,repurchases bytheCompanymayonlybemadeoutofprofitsofthe Companyoroutoftheproceedsofafreshissueofshares madeforthepurpose,or,outofcapitalifsoauthorizedby theArticlesofAssociationandsubjecttoandinaccordance withtheCompaniesAct. Any premium payable on repurchase must be 購回產生的任何應付溢價必須在按照公司法規定 paid outofprofitsoftheCompanyoroutofthe 之方式購回股份之前或之時，以本公司利潤或本 Company’s share premium account before or 公司股份溢價賬進行支付。 at the time the Shares are repurchased in the mannerprovidedintheCompaniesAct. 5. EFFECTOFEXERCISINGTHEREPURCHASE 5. 行使購回授權之影響 MANDATE Taking into account of the current working capital position of the Company, the Directors 考慮到本公司現時之營運資金狀況，董事認為，倘 consider that, if the Repurchase Mandate were 購回授權獲全面行使，與最近期刊發之經審核賬目 to be exercised in full, it might have a material 所披露之狀況相比，其可能對本公司之營運資金 adverse effectontheworkingcapitaland/orthe 及/或資本負債狀況造成重大不利影響。 gearing position of the Company as compared with the position disclosed in the most recent publishedauditedaccounts. The Directors do not intend to exercise the Repurchase Mandate to such an extent as would, 倘於若干情況下行使購回授權將會對董事認為本 in the circumstances, have a material adverse 公司宜不時具備的營運資金需要或資產負債狀況 effect on the working capital requirements or the 構成重大不利影響，則董事擬不行使購回授權。 gearing position of the Company which in the opinion of the Directors are from time to time appropriatefortheCompany. 6. DIRECTORS’ UNDERTAKING 6.董事承諾 None of the Directors nor, to the best of their 目前，概無董事或（經彼等作出一切合理查詢後 knowledge having made all reasonable enquiries, 所深知）彼等之任何聯繫人士，有意在購回授權 any oftheirassociates currently intendstosellany 獲股東批准之情況下根據購回授權向本公司或其 Shares to the Company or its subsidiaries under 附屬公司出售任何股份。 the Repurchase Mandate if the Repurchase Mandateisapproved bytheShareholders. APPENDIX1EXPLANATORYSTATEMENTONTHEREPURCHASEMANDATE 附錄一購回之說明文件The Directors have undertakentothe Stock Exchange董事已向聯交所承諾，於適當情況下，彼等將根that, so far as the same may be applicable,they will據創業板上市規則、組織章程細則、公司法及開exercisethepowertomakerepurchasepursuantto 曼群島任何其他適用法例進行購回。 the Repurchase Mandate inaccordancewiththe GEMListingRules,theArticlesofAssociation,the Companies Lawandanyotherapplicable lawsof theCayman Islands. No connected personoftheCompanyhas notified 概無本公司關連人士知會本公司，其現時有意在購 the Company that he has a present intention to 回授權獲授予情況下，向本公司出售任何股份，或 sell any Shares to the Company, nor has any such 承諾不會向本公司出售其持有任何股份。 connected person undertaken not to sell any Shares held by him to the Company in the event thattheRepurchaseMandateisgranted. 7.EFFECTOFTAKEOVERSCODEAND PUBLICFLOAT 7.收購守則影響及公眾持股量If, as a result of a repurchase of Shares by the Company, a Shareholder’s proportionate interest 倘本公司購回股份後股東所占本公司投票權權益in the voting rights of the Company increases, 比例有所增加，則就收購守則規則32而言，有such increase will be treated as an acquisition for 關增加將被視為一項收購。因此，一名或一群 the purpose of Rule 32 of the Takeovers Code. 一致行動股東（定義見收購守則）可取得或整合 Accordingly, a Shareholder or group of 本公司控制權，且鬚根據收購守則規則26及32 Shareholders acting in concert (as defined in the 提出強制收購要約。 Takeovers Code) could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and32 oftheTakeoversCode. As at the Latest Practicable Date,tothe bestofthe 於最後可行日期，就董事所深知及確信，下列股 knowledgeand belief ofthe Directors,thefollowing Shareholders are interested in 5% or more of the 東擁有本公司已發行股本5%或以上權益。根據最Company’s issued share capital. Based on the 後可行日期存檔權益披露，郭夏先生及其受控法 disclosure of interest filings as at the Latest 團、 Practicable Date, Mr. Guo Xia and its controlled WinslandAgentsLimited、Venturepharm corporations, Winsland Agents Limited, HoldingsInc及BrightExcelAssetsLimited分別 Venturepharm Holdings Inc. and Bright Excel Assets 控制本公司13.35%、34.78%、35.10%及 Limited respectively controlled 13.35%, 35.10%, 15.01%及 9.23%投票權（或合共控制 72.69% 15.01% and 9.23%voting rights inthe Company (or 投票權）。倘董事全面行使購回股份購回授權， 72.69% voting rights in aggregate). Inthe eventthe Winsland Directors exercise infullthe Repurchase Mandateto AgentsLimited或不會被視為已觸發須 repurchase Shares, subject to the relevant 根據收購守則規則26提出強制收購要約責任，惟 shareholder’s consultation with the Executive, 待有關股東向執行人員作出諮詢後方可作實。董 Winsland Agents Limited may or may not be 事現時無意行使購回授權以致觸發任何股東鬚根據 regarded as have triggered the mandatory offer 收購守則提出強制收購要約責任。 obligationunderRule26oftheTakeoversCode.The Directors do not have any present intention to exercise the Repurchase Mandate to such an extent as would trigger the mandatory offer obligation of anyshareholderundertheTakeoversCode. APPENDIX1EXPLANATORYSTATEMENTONTHEREPURCHASEMANDATE 附錄一購回之說明文件 The GEM Listing Rules prohibit a company from making 根據創業板上市規則規定，倘若購回會導致公 repurchase on the Stock Exchange if the result of the 眾持股量少於已發行股本25%（或聯交所厘定 repurchase would be that less than 25% (or such other 其他指定最低百分比），則公司不得在聯交所 prescribed minimum percentages determined by the 購回股份。董事無意行使購回授權以致公眾人 Stock Exchange) of the issued share capital would be in 士所持股份數目跌至低於所規定最低百分比 public hands.The Directors have no intentiontoexercise 25%。 theRepurchaseMandatetosuchanextentthatwillresult inthe number of Shares in hands of publicfalling below theprescribedminimumpercentageof25%. 8.本公司購回股份 8.SHAREREPURCHASEMADEBYTHECOMPANY TheCompanyhadnotpurchasedanyofitsShares(whether 截至最後實際可行日期止六個月，本公司並無 ontheStockExchangeorotherwise)duringtheprevioussix 購回股份（不論於聯交所或其他交易所）。 monthsprecedingtheLatestPracticableDate. 9.股份價格 9. SHAREPRICESThe Shares aretradingonthe Stock Exchangeand 截至最後實際可行日期止十二個月期間，股份 the highest and lowest prices at which the Shares 於聯交所的每月最高及最低成交價如下： have been traded on the Stock Exchange in each of the following months immediately preceding theLatestPracticableDateareasfollows: Highesttraded price Lowesttradedprice 股票價格最高價 股票價格最低價 HK$ HK$ 月份 港元 港元 Month 二零二五年 2025 六月 0.195 0.151 June 七月 July 0.198 0.162 八月 August 0.185 0.160 九月 September 0.198 0.146 十月 October 0.184 0.160 十一月 November 0.159 0.141 十二月 December 0.156 0.131 2026 二零二六年 一月 January 0.155 0.136 二月 February 0.160 0.136 三月 March 0.160 0.122 四月 五月 April 0.149 0.128 六月（截 May 0.138 0.124 至最後實 June(uptothe 際可行日 0.101 0.120 LatestPracticable EXECUTIVEDIRECTOR 執行董事 Mr.GUOXia,aged61,istheChairmanandanexecutiveDirector.Heis 郭夏先生，61歲，本集團主席、執行董事。他也是公司提 alsoamemberofthenominationcommitteeandremunerationcommittee 名委員會和薪酬委員會的成員。他負責本集團之策略規劃 oftheCompany.Mr.GUOXiaisresponsibleforstrategicplanningand 及發展、整體管理。郭夏先生畢業於多倫多大學藥學院研 development,overallmanagementoftheGroup.Mr.GUOXiaobtained 究生院獲碩士學位，亦在Heriot-WattUniversity完成工 withaMasterdegreeinsciencefromUniversityofTorontoinMarch 商管理碩士學位和英國劍橋大學JudgeinstituteEMBA之 1997.Mr.GUOXiahasalsocompletedvariousapprovedcoursesforthe degreeofMasterofBusinessAdministrationinHeriot-WattUniversity多個認可課程。於一九九八年十二月成立本集團之前，郭 andtheJudgeinstituteEMBAinUniversityofCambridge.Before 夏先生曾於美國瓊森公司旗下之OrthoMcNeilInc.及Teva establishingtheGroupinDecember1998,Mr.GUOXiahadworkedfor PharmaceuticalIndustriesLtd旗下NovopharmLimited twopharmaceuticalcompaniesinCanada,namelyOrthoMcNeilInc. 分別擔任研究科學家及工序開發經理。郭夏先生還曾經擔 underJohnson&JohnsonandNovopharmLimitedunderTeva 任過美國NASDAQ上市公司CommonWealthTechnologyINC PharmaceuticalIndustriesLtdasresearchscientistandprocess 公司的董事長和CEO。郭夏先生擔任中華全國工商聯醫藥副 developmentmanager,respectively.Mr.GUOXiausedtobethedirector會長並獲得中國國務院授予全國勞動模範稱號，全國五一 andCEOofCommonWealthTechnologyInclistedonNASDAQand vicepresidentofAll-ChinaFederationofIndustryandCommerce 勞動獎章。二零零五並被英國商會（BCCC）授予“二零零 MedicalPharmaceuticalChamber,healsogotNationalmodelworkertitle五優秀創新企業家”（並資助劍橋大學EMBA學習）。 andTheNationalMay1LabourMedal,andwasprizedas‘2005 Excellentcreativeenterpriser’in2005byBCCC(gotthescholarshipforEMBAstudyinUniversityofCambridge). 郭夏先生已與本公司訂立服務協議，自二零二五年一月一 Mr.GuoXia,hasenteredintoaserviceagreementwiththeCompanyfor 日起至二零八年十二月三十一日。 atermcommencingfrom1January2025to31December2028. 於最後可行日期，WinslandAgentsLimited（郭 AsattheLatestPracticableDate,WinslandAgentsLimited,a 夏先生全資擁有的公司）持有該公司的實益所有權 companywhollyownedbyMr.GUOXia,heldbeneficial 。郭夏先生全資擁有的公司WinslandAgents ownershipof349,368,873Shares.Furthermore,Venturepharm Limited實益擁有349,368,873股股份。此外，由 HoldingsInc.,whichapproximately49.00%ofitsshareswereheld byWinslandAgentsLimitedandapproximately47.63%ofits WinslandAgentsLimited持有其約49.00%股shareswereheldbyMr.GUOXia,heldbeneficialownershipof 份及郭夏先生持有其約47.63%股份的 149,432,583Shares.Additionally,BrightExcelAssetsLimited,a VenturepharmHoldingsInc.149,432,583股股 companywhollyownedbyVenturepharmHoldingsInc.,held 份的實益所有權。此外，VenturepharmHoldings beneficialownershipof91,915,181shares.Consequently,Mr.GUO Xiaisconsideredtohavebeneficialinterestintheaforementioned Inc.全資擁有的BrightExcelAssetsLimited SharesundertheSecuritiesandFuturesOrdinance(“SFO” 持有91,915,181股股份的實益所有權。因此，根 ).Combiningthiswiththe132,851,941sharesdirectlyownedby 據《證券及期貨條例》，郭夏先生被視為擁有上述 Mr.GUOXia,hisbeneficialownershiptotheCompanyamounts to723,568,578Shares. 股份的實益權益。連同郭夏先生直接擁有的132, 851,941股股份，郭夏先生對本公司的實益擁有權 為723,568,578股股份。 INDEPENDENTNON-EXECUTIVEDIRECTOR 獨立非執行董事 Mr.GuoTong,aged58,iscurrentlytheViceChairmanoftheClinicalTrials郭彤先生，58歲，目前擔任中國醫藥創新促進會臨床試 CommitteeandDataScienceWorkingGroupLeaderoftheChina 驗專委會副主任委員及數據科學工作組組長；清華大學 PharmaceuticalInnovationandResearchDevelopmentAssociation;alecture醫學院健康領導力碩士班授課導師。郭彤先生在臨床試 instructoroftheMaster'sPrograminHealthLeadershipatTsinghua 驗設計及分析，真實世界研究，醫療大數據及人工智慧 UniversityMedicalCollege.Mr.GuoTonghasextensiveresearch experienceinclinicaltrialdesignandanalysis,real-worldresearch,medical 應用方面有著非常豐富的研究經驗。郭彤先生擁有加拿 bigdataandartificialintelligenceapplications.Mr.GuoTongholdsa大麥吉爾大學生物統計學碩士及博士學位。 master'sdegreeinbiostatisticsandaPhDfromMcGillUniversity,Canada..郭彤先生已與本公司訂立為期三年的服務協議，自二零二六 Mr.GuoTonghasenteredintoaserviceagreementwiththeCompany 年四月十四日起計。 foratermof3yearscommencingon14April2026.Pursuantto thetermsofhisserviceagreement,Mr.GuoTongisnotentitledto anydirector’sfee.. 除該披露外，郭彤先生不在《證券及期貨條例》第XV部所指的本公司股份及關股份中擁有任何權益。 Saveasdisclosed,Mr.GuoTongdoesnothaveany interestsinsharesandunderlyingsharesoftheCompanywithinthe meaningofPartXVoftheSFO. INDEPENDENTNON-EXECUTIVEDIRECTOR 獨立非執行董事 Ms.LIUNa("Ms.Liu"),aged51,hasbeenappointedasanindependentnon-劉娜女士("劉女士")，五十一歲，於二零二四年三月十 executiveDirectorandthechairmanoftheauditcommitteesince12March二日被任命為獨立非執行董事及審核委員會主席。劉女 2024.Ms.LiuholdsaBachelor'sDegreeinStatistics,QualifiedasaCertifiedPublicAccountant(CPA),aCertifiedTaxAccountant(CTA),alawyerin 士本科獲統計學學士，擁有中國註冊會計師（CPA）、 China,andasecuritiespractitioner.Ms.Liuhasmorethan10yearsof 註冊稅務師、中國律師資質，具備證券從業資格。劉女 experienceinfinanceperformanceandmanagement,shehasworkedasan士擁有十年以上的財務履職和管理經驗，彼先後在世界 analystinAgriculturalDevelopmentBankofChina (Fortune500),afinancemanagerinBertelsmanngroupChinaregion 500強中國農業發展銀行任分析員、世界500強企業德國 (Fortune500),afinancedirectorinHafeleHardware(China)Ltd.,andaVice貝塔斯曼集團中國區任財務經理（Bertelsmanngroup GMofIMDinCenturySecuritiesCo.,Ltd. ）、海福樂五金（中國）有限公司任財務總監、世紀證 券有限責任公司任部門副總經理。 劉娜女士已與本公司訂立服務協議，自二零二四年三 Ms.LIUNa,,hasenteredintoaserviceagreement 月十二日起為期三年。。 withtheCompanyforatermof3yearscommencingon12 March2024. Saveasdisclosed,Ms.LIUNa,doesnothaveanyinterestsinsharesand除該披露外，劉娜女士不在《證券及期貨條例》第 underlyingsharesoftheCompanywithinthemeaningofPartXVoftheSFO.XV所指的本公司股份及相關股份中擁有任何權益。 《公司章程大綱及細則》的擬議修訂詳情如下。現有《公司章程大綱及細則》的變更以紅色下劃線（新插入）或劃掉（刪除）顯示。 開曼群島 公司法（修訂版） 股份有限公司 中國醫療集團有限公司 （CHINAHEALTHGROUPINC） 第三次修訂重述後的公司章程大綱 （2026年7月17日通過的特殊決議所採納） 1、公司的名稱是：中國醫療集團有限公司 2 、公司的註冊辦公所在地位於開曼群島大開曼島西灣道802號芙蓉路宏閣郵箱31119，KY1-1205Vistra(Cayman)Limited的辦公室，或者隨時由董事會決定的開曼群島內的其他地點。 3、本公司的設立目的是不受限制的，應該包括但不局限於以下方面：(i) 作為投資公司或投資控股公司開展業務，獲取和持有由任何性質或任何地點組建或開展業務的任何公司、企業或企業單位所發行或擔保的股份、股票、公司債券、債票、抵押、債務和證券，及由 任何政府、統治者、委員、信託、地方當局或其他公共團體所發行或擔保的股份、股票、公司債券、債票、抵押、債務和其他證券；以及隨時針對當時的公司投資進行暫時的改變、轉調、處置及處理； (ii) 有條件或無條件地認購、承銷、代銷，或者取得、持有、買賣及轉換股票、股份和各類證券；與任何個人或公司就分享利潤、互惠互利或合作達成合作關係或達成任何安排；促進和幫助促進任何類型的公司、合資企業、集團或合夥企業的設立、組成或創辦，目的是：取得本公司的任何財產並承 擔任何負債，或者，直接或間接地推進本公司的設立目的，或者，公司可能認為有利的任何其他目的。 (iii) 行使或執行任何股份、股票、債券或其他證券所賦予的或附帶的所有權利和權力，包括但不影響：公司因擁有已發行的特定比例或票面價值而被授予的上述所有此類投票權或控制權的上述所有權 (iv) 就任何個人、單位元或公司履行其全部或任何義務提供保證或擔保、賠償、支援或保護，無論該個人、單位或公司是否以任何方式與本公司有關聯或隸屬於本公司，以及無論是否在目前及將來通過針對本公司的全部或部分事業、財產和資產達成個人契約或抵押、收費或留置權（包括其未催繳股本）， 或者通過任何此類方式，無論本公司是否將因此而取得有值對價。 (v) （a）從事促進者和企業家的業務；從事金融家、資本家、特許經營者、商人、經紀人、貿易商、經銷商、代理商、進口商和出口商的業務；承接並從事各類投資、金融、商業、交易、貿易及其他業務 （b）作為負責人、代理人或其他方，從事開發商、顧問、地產代理或經理、建築商、承包商、工程師、製造商、所有類型財產（包括服務）經銷商或供應商的業務。（未完）  |